Clinical trials in Duchenne dystrophy. Standardization and reliability of evaluation procedures.
暂无分享,去创建一个
M. Province | S. Pandya | J. Florence | W. King | J. Robison | L. Signore | M. Wentzell | Michael A. Province | Julaine Florence | Shree Pandya | Wendy M. King | Mindy Wentzell | M. Province
[1] J. Miller,et al. Clinical investigation in duchenne dystrophy: 2. Determination of the “power” of therapeutic trials based on the natural history , 1983, Muscle & nerve.
[2] M. Brooke,et al. Clinical trial in duchenne dystrophy. I. The design of the protocol , 1981, Muscle & nerve.
[3] V. Dubowitz. A Clinician's View of Neuromuscular Diseases , 1978 .
[4] M. Brooke,et al. Evaluation of the child with muscular weakness. , 1978, The Orthopedic clinics of North America.
[5] W. Thomson,et al. X-linked recessive (Duchenne) muscular dystrophy (DMD) and purine metabolism: effects of oral allopurinol and adenylate. , 1978, Metabolism: clinical and experimental.
[6] P. Vignos,et al. Management of progressive muscular dystrophy in childhood. , 1963, JAMA.
[7] R. L. Plackett,et al. The Analysis of Variance , 1960 .
[8] C. Baker. Confined to bed. , 1953, Guy's Hospital gazette.
[9] J. Mendell,et al. Lack of benefit of allopurinol in duchenne dystrophy , 1979, Muscle & nerve.